Pharis Mohideen - DBV Technologies Chief Officer
| DBVT Stock | USD 3.45 0.04 1.15% |
Insider
Pharis Mohideen is Chief Officer of DBV Technologies
| Age | 59 |
| Address | 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120 |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
Latest Insider Transactions
Pharis Mohideen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pharis Mohideen against DBV Technologies stock is an integral part of due diligence when investing in DBV Technologies. Pharis Mohideen insider activity provides valuable insight into whether DBV Technologies is net buyers or sellers over its current business cycle. Note, DBV Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell DBV Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pharis Mohideen over two weeks ago Disposition of 342 shares by Pharis Mohideen of DBV Technologies at 0.53 subject to Rule 16b-3 | ||
Pharis Mohideen over three months ago Acquisition by Pharis Mohideen of 115000 shares of DBV Technologies at 3.07 subject to Rule 16b-3 | ||
Pharis Mohideen over six months ago Disposition of 660 shares by Pharis Mohideen of DBV Technologies at 1.36 subject to Rule 16b-3 | ||
Pharis Mohideen over six months ago Sale by Pharis Mohideen of 2245 shares of DBV Technologies |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.4625) % which means that it has lost $0.4625 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0311) %, meaning that it created substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, DBV Technologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 3.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 31 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Lappe | Inhibrx | 57 | |
| Hing Wong | HCW Biologics | 70 | |
| CPA CPA | Oric Pharmaceuticals | 47 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Jason CPA | MediciNova | 46 | |
| MAICD MAICD | Opthea | 48 | |
| Ryan Baker | Iteos Therapeutics | N/A | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Thomas Baetz | Genfit | 50 | |
| Matthew MBA | Iteos Therapeutics | 51 | |
| David Grainger | Centessa Pharmaceuticals PLC | 55 | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| Saurabh MD | Centessa Pharmaceuticals PLC | 48 | |
| Lori Friedman | Oric Pharmaceuticals | 60 | |
| Tia Bush | Centessa Pharmaceuticals PLC | 53 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| MD MBA | Opthea | N/A | |
| Igor MD | Celcuity LLC | N/A | |
| John CPA | MediciNova | N/A | |
| Joanne MD | Iteos Therapeutics | 52 | |
| Susan MS | Eliem Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Caroline Daniere, Chief Staff | ||
| Daniel Tass, CEO Director | ||
| Edward MBA, Senior America | ||
| Alan Kerr, Senior Affairs | ||
| Pascal Wotling, Chief Officer | ||
| Pharis Mohideen, Chief Officer | ||
| Virginie MBA, CFO Officer | ||
| Katie Matthews, Investor Officer | ||
| Lucie Mondoulet, Director of Research Department | ||
| Anne Pollak, Head Relations | ||
| Michele Robertson, Chief Officer |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (28.29) % | ||||
| Current Valuation | 32.96 M | ||||
| Shares Outstanding | 19.24 M | ||||
| Shares Owned By Institutions | 16.70 % | ||||
| Number Of Shares Shorted | 1.26 M | ||||
| Price To Earning | (8.25) X | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 5.37 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for DBV Stock Analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.